Halozyme Therapeutics, Inc. (HALO) Posts Q1 Loss of 22c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Halozyme Therapeutics (HALO) Q1 Report 'Solid' on Multiple Fronts - BMO Capital
May 13, 2014 6:26 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $24 price target on Halozyme Therapeutics (NASDAQ: HALO) following Q1 results which showed a strong HERCEPTIN SC launch, and progress on the PEGPH20 clinical hold as the company announced that the Data... More



